Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487231 | 0.78 | MAPK1 (0.48) | CES1KCNN4MAPK1CA1CA2 | |
| SCHEMBL8318529 | 0.75 | NR3C2 (0.43) | KCNN4NR3C2MAPK1CA1CA2 | |
| SCHEMBL8317668 | 0.74 | CA1 (0.40) | MAPK1CA1CA2CA9ALDH1A1 | |
| SCHEMBL6270358 | 0.73 | MAPK1 (0.44) | CES1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL7538122 | 0.72 | VDR (0.43) | MAPK1CA1CA2CA9ALDH1A1 | |
| SCHEMBL27290020 | 0.71 | CES1 (0.41) | CES1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL27684711 | 0.71 | NR3C2 (0.40) | CES1KCNN4NR3C2MAPK1CA1 | |
| SCHEMBL8318293 | 0.71 | NR3C2 (0.38) | KCNN4NR3C2MAPK1CA1CA2 | |
| SCHEMBL7056377 | 0.70 | MAPK1 (0.41) | CES1KCNN4MAPK1ALDH1A1ALOX15 | |
| SCHEMBL27559567 | 0.70 | MAPK1 (0.41) | CES1KCNN4MAPK1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | claimed |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | GUTMAN DANIELA (IL) | 2004-08-26 | — | — | US | claimed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | claimed |
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-23 | — | — | US | claimed |
| CN-1273581-A | Process and reagent for N-alkylation of ureides | TARO PHARMA IND (IL) | 2000-11-15 | — | — | CN | claimed |
| US-6093820-A | REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-07-25 | — | — | US | claimed |
| US-RE38934-E1 | Method and reagents for N-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-01-10 | — | — | US | disclosed |
| EP-1027339-B1 | METHOD AND REAGENTS FOR N-ALKYLATING UREIDES | TARO PHARMA IND (IL) | 2004-01-02 | — | — | EP | disclosed |
| US-6664262-B2 | N-methoxymethyl-5,5-diphenylbarbituric acid | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2003-12-16 | — | — | US | disclosed |
| EP-1342718-A1 | Method and reagents for n-alkylating ureides | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018080-A1 | N-methoxymethyl-5,5-diphenylbarbituric acid | MGMT, ALKBH3, ALKBH5 | CES1 1740/4885KCNN4 459/4885NR3C2 1117/4885 |
| US-20040167358-A1 | Method and reagents for N-alkylating ureides | MGMT, ETV6, ALKBH3 | CES1 2168/4885KCNN4 499/4885NR3C2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.